PURPOSE: IRANIAN RENAL CALCIUM STONE FORMERS SEEMS TO HAVE LOW URINE CALCIUM, MAY BE DUE TO LESS CALCIUM INTAKE FOR THEIR DIETARY REGIMEN. IN THE ARENA OF MORE CALCIUM INTAKE RECOMMENDATION, THE EFFECT OF CALCIUM SUPPLEMENTS ON URINARY METABOLITES OF SUCH PATIENS AS A POSSIBLE RISK FACTOR FOR STONE FORMING IS NOT WELL-KNOWN. METHODS & MATERIALS: 27 ACTIVE CALCIUM RENAL STONE FORMERS INCLUDING 10 WOMEN AND 17 MEN (37% & 63%) WITH MEAN AGE OF 44.7 YEAR OLD (19-73) WERE EVALUATED BY SERUM & URINE CHEMICAL METABOLITE ANALYSIS. IMAGING STUDIES WERE UNREVEALING. ORAL CALCIUM CARBONATE 1 G PER DAY WERE ADMINISTERED FOR 3 WEEKS & THE DATA REAPPRAISED. RESULTS: MEAN URINE METABOLITES WERE RESPECTIVELY AS: MAGNESIUM (100, 104 MG, P=0.008), PHOSPHOROUS (644, 608 MG, P=0.04), CALSIUM (226, 332 MG P<0.0001), CITRATE (376, 359 MG, P=0.001), POTASSIUM (71, 64 MG, P=0.01), OXALATE (23.3, 22 MG, P=0.8), URIC ACID (740, 706 MG, P=0.12), SODIUM (271, 263 MG, P=0.2), CREATININE (1361, 1320 MG, P=0.5). SERUM METABOLITES WERE NOT CHANGED SIGNIFICANTLY. DISCUSSION: PRIMARY URINARY OXALATE, URIC ACID & SODIUM LEVELS IN THESE PATIENTS WERE USUALLY IN THE UPPER LIMITES OF NORMAL WHILE CITRATE AND CALCIUM WERE IN THE LOWER LIMITS THAT MAY BE DUE TO FEEDING REGIMEN. CALCIUM SUPPLEMENTETION RAISES URINARY CALCIUM & MAGNESIUM LEVEL WHILE PHOSPHOROUS, CITRATE & POTASSIUM DECREASE SIGNIFICANTLY. HOWERE ALL OF THE MEASURES WERE WITHIN THE NORMAL LIMITS. ORAL CALCIUM SUPPLEMENTS HAS NOT DETRIMENTAL EFFECT ON URINARY METABOLITE PARAMETERES IN RENAL CALCIUM STONE FORMERS.